Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...

The biomarkers, identified using Liquid's EMERGE platform, demonstrated a 95% sensitivity and 98% specificity in detecting pancreatic cancer across multiple study cohorts. These promising results ...

Furthermore, existing biomarkers, such as CA19-9, are not reliable on their own to detect early-stage pancreatic cancer. Goel, Xu, and colleagues explored the potential of an exosome-based liquid ...

Löhr. "Unlike traditional imaging, which requires specific equipment and expertise, liquid biopsy could become a widely accessible tool for early detection." With pancreatic cancer being one of ...

A new blood test could diagnose pancreatic cancer ... As with most types of cancer, once the tumor has spread, it becomes much harder to successfully treat. “Liquid biopsy” tests which use ...